3. Umbruch 4.4..2005 - Online Pot
3. Umbruch 4.4..2005 - Online Pot
3. Umbruch 4.4..2005 - Online Pot
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
180 L. De Petrocellis et al.<br />
diation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured<br />
HL-60 myeloblastic leukemia cells. Leuk Lymphoma 44: 1767–1773<br />
78 Baek SH, Kim YO, Kwag JS, Choi KE, Jung WY, Han DS (1998) Boron trifluoride etherate on<br />
silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral<br />
epitheloid carcinoma cells. Arch Pharmacol Res 21: 353–356<br />
79 Recht LD, Salmonsen R, Rosetti R, Jang T, Pipia G, Kubiatowski T, Karim P, Ross AH, Zurier R,<br />
Litofsky NS, Burstein S (2001) Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive<br />
cannabinoid. Biochem Pharmacol 62: 755–763<br />
80 Bidinger B, Torres R, Rossetti RG, Brown L, Beltre R, Burstein S, Lian JB, Stein GS, Zurier RB<br />
(2003) Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes.<br />
Clin Immunol 108: 95–102<br />
81 Guzman M, Galve-Roperh I, Sanchez C (2001) Ceramide: a new second messenger of cannabinoid<br />
action. Trends Pharmacol Sci 22: 19–22<br />
82 Gomez Del Pulgar T, De Ceballos ML, Guzman M, Velasco G (2002) Cannabinoids protect astrocytes<br />
from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase<br />
B pathway. J Biol Chem 277: 36527–36533<br />
83 Molina-Holgado E, Vela JM, Arevalo-Martin A, Almazan G, Molina-Holgado F, Borrell J, Guaza<br />
C (2002) Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid<br />
receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 22: 9742–9753<br />
84 van der Stelt M, Veldhuis WB, Maccarrone M, Bar PR, Nicolay K, Veldink GA, Di Marzo V,<br />
Vliegenthart JF (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system.<br />
Mol Neurobiol 26: 317–346<br />
85 Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin<br />
Pharmacokinet 42: 327–360<br />
86 Malan TP Jr, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F (2003) CB2 cannabinoid<br />
receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 3: 62–67<br />
87 Bifulco M, Di Marzo V (2002) Targeting the endocannabinoid system in cancer therapy: a call for<br />
further research. Nat Med 8: 547–550<br />
88 Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD (2002) Respiratory and immunologic<br />
consequences of marijuana smoking. J Clin Pharmacol 42: 71S–81S<br />
89 (2003) Cannabis-based medicines–GW pharmaceuticals: high CBD, high THC, medicinal<br />
cannabis–GW pharmaceuticals, THC:CBD. Drugs R D 4: 306–309<br />
90 Pertwee RG, Gibson TM, Stevenson LA, Ross RA, Banner WK, Saha B, Razdan RK, Martin BR<br />
(2000) O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties.<br />
Br J Pharmacol 129: 1577–1584<br />
91 Pertwee RG (2000) Cannabinoid receptor ligands: clinical and neuropharmacological considerations,<br />
relevant to future drug discovery and development. Expert Opin Invest Drugs 9: 1553–1571<br />
92 Di Carlo G, Izzo AA (2003) Cannabinoids for gastrointestinal diseases: potential therapeutic<br />
applications. Expert Opin Invest Drugs 12: 39–49<br />
93 Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001) Cannabinoids<br />
for control of chemotherapy induced nausea and vomiting: quantitative systematic review. Br Med<br />
J 323: 16–21<br />
94 Walsh 2003 and James JS (2000) Marijuana safety study completed: weight gain, no safety problems.<br />
AIDS Treat News 348: 3–4<br />
95 Barann M, Molderings G, Bruss M, Bonisch H, Urban BW, Gothert M (2002) Direct inhibition by<br />
cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site.<br />
Br J Pharmacol 137: 589–596<br />
96 Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA (2003) Delta9-tetrahydrocannabinol<br />
selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit<br />
emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285: G566–G576<br />
97 Darmani NA (2001) Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced<br />
emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.<br />
Pharmacol Biochem Behav 69: 239–249<br />
98 Darmani NA, Johnson JC (2004) Central and peripheral mechanisms contribute to the antiemetic<br />
actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J<br />
Pharmacol 488: 201–212<br />
99 Darmani NA, Janoyan JJ, Kumar N, Crim JL (2003) Behaviorally active doses of the CB1 receptor<br />
antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol
Change language